Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Weiser

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
Early Intervention in Psychiatry|October 28, 2014
Screening tools for clinical high risk for psychosisJean Addington, Jacqueline Stowkowy, Mark Weiser
The British Journal of Psychiatry : the Journal of Mental Science|September 2, 2005
Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypesMark Weiser, Jim van Os, Michael Davidson
The Cochrane Database of Systematic Reviews|September 19, 2014
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsTamir Epstein, Nikolaos A Patsopoulos, Mark Weiser
The Cochrane Database of Systematic Reviews|May 27, 2016
WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsTamir Epstein, Nikolaos A Patsopoulos, Mark Weiser
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|September 17, 2003
[Use of cannabis in adolescence and risk of schizophrenia]Karla Soares-Weiser, Mark Weiser, Michael Davidson
The Israel Medical Association Journal : IMAJ|October 18, 2020
Three Cases of COVID-19-related First Onset Brief Reactive PsychosisSol Jaworowski, Mark Weiser, Cornelius Gropp, et al.
Journal of Affective Disorders|April 19, 2026
Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase studyMohammed Aboukaoud, Bosmat Hoch, Mark Weiser, et al.
Schizophrenia Research|December 1, 2010
Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSSLiron Rabany, Mark Weiser, Nomi Werbeloff, et al.
American Journal of Medical Genetics|November 29, 2002
Clinical characteristics of adolescents later hospitalized for schizophreniaMark Weiser, Haim Y Knobler, Shlomo Noy, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 19, 2016
The association between cannabis use and anxiety disorders: Results from a population-based representative sampleDaniel Feingold, Mark Weiser, Jürgen Rehm, et al.
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
Early Intervention in Psychiatry|October 28, 2014
Screening tools for clinical high risk for psychosisJean Addington, Jacqueline Stowkowy, Mark Weiser
The British Journal of Psychiatry : the Journal of Mental Science|September 2, 2005
Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypesMark Weiser, Jim van Os, Michael Davidson
The Cochrane Database of Systematic Reviews|September 19, 2014
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsTamir Epstein, Nikolaos A Patsopoulos, Mark Weiser
The Cochrane Database of Systematic Reviews|May 27, 2016
WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adultsTamir Epstein, Nikolaos A Patsopoulos, Mark Weiser
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|September 17, 2003
[Use of cannabis in adolescence and risk of schizophrenia]Karla Soares-Weiser, Mark Weiser, Michael Davidson
The Israel Medical Association Journal : IMAJ|October 18, 2020
Three Cases of COVID-19-related First Onset Brief Reactive PsychosisSol Jaworowski, Mark Weiser, Cornelius Gropp, et al.
Journal of Affective Disorders|April 19, 2026
Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase studyMohammed Aboukaoud, Bosmat Hoch, Mark Weiser, et al.
Schizophrenia Research|December 1, 2010
Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSSLiron Rabany, Mark Weiser, Nomi Werbeloff, et al.
American Journal of Medical Genetics|November 29, 2002
Clinical characteristics of adolescents later hospitalized for schizophreniaMark Weiser, Haim Y Knobler, Shlomo Noy, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 19, 2016
The association between cannabis use and anxiety disorders: Results from a population-based representative sampleDaniel Feingold, Mark Weiser, Jürgen Rehm, et al.
Pageof 18